Clinical Trial

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Study acronym: FILIOS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
Protocol Amendment History 1 change
notable Primary completion moved earlier: 2026-03-11 -> 2026-01-28 2026-04-22
Trial Details
NCT Number NCT06869785
Lead Sponsor Novartis Pharmaceuticals
Conditions Relapsing Multiple Sclerosis (RMS)
Enrollment 196 participants
Start Date 2025-03-13
Primary Completion 2026-01-28 (estimated)
Study Completion 2030-03-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-10